Profound Medical
NASDAQ: PROFMississauga · Founded 2015 · 182 employees on LinkedIn · 3 known investors
Find your way into Profound Medical
Each arrow is one introduction. Sign up to fill in the first one.
Ask Art Bailey to introduce you to Arun Menawat
You →Art · together at Novadaq Technologies Inc. →Arun
Ask Jamie Chen to introduce you to Rashed Dewan
You →Jamie · together at Profound Medical →Rashed
Sign up to find every way you can get introduced to Profound Medical
- Your email: who you already know at Profound Medical, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Profound Medical team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Profound Medical develops real-time MRI-guided thermal ultrasound systems for incision-free ablation of abnormal or cancerous tissue. The company's TULSA-PRO therapeutic system enables precise ablation of diseased prostate tissue in a commercial-stage medical technology setting.
Founders & leadership


Board


Investors · 3
How we know: CTI Life Sciences Fund L.P.'s portfolio page · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$877.5K disclosed across 1 round · 2017
▶$877.5KraisedOct 2017 · 16 investors · BiotechnologyRule 506(b)
- Jean-Francois PariseauDirector
- Damian LambDirector
- Arun MenawatExecutive Officer, Director
- William CurranDirector
- Samira SakhiaDirector
- Kenneth GalbraithDirector
- Rashed DewanExecutive Officer
- Offering amount
- $877.5K
- Amount sold
- $877.5K
- Sales commissions
- $52.6K
- Placement agents
- CIBC World Markets Corp.
- First sale
- Sep 2017
- Incorporated
- Corporation, Ontario, Canada, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Profound Medical do?
- Profound Medical develops real-time MRI-guided thermal ultrasound systems for incision-free ablation of abnormal or cancerous tissue. The company's TULSA-PRO therapeutic system enables precise ablation of diseased prostate tissue in a commercial-stage medical technology setting.
- Who are Profound Medical's investors?
- Profound Medical's investors include CTI Life Sciences Fund L.P., FACIT (Fight Against Cancer Innovation Trust), Genesys Capital.
- How much funding has Profound Medical raised?
- Profound Medical has disclosed $877.5K raised across 1 round.
- Where is Profound Medical headquartered?
- Profound Medical is headquartered in Mississauga.



